Non-Alcoholic Steatohepatitis Treatment Market Research 2024-2033: Outlook, Overview, and Competitor Analysis

"The new report published by The Business Research Company, titled ""Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $1.89 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%. The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Insulin Resistance Surge Fueling Growth In The Non-Alcoholic Steatohepatitis Treatment Market
An increased prevalence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market going forward. Insulin resistance occurs when muscles, fat, and liver cells do not respond adequately to insulin and cannot easily absorb glucose from the blood, causing high blood sugar. These are linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The use of insulin resistance has multiplied due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, according to a report from International Diabetes Federation, a Belgium-based global diabetes community, diabetes affects 537 million individuals (20-79 years old), accounting for one in every ten, which is expected to increase to 643 million by 2030 and 783 million by 2045. Furthermore, in March 2023, according to a report published by the Office for Health Improvement and Disparities, a UK government department, the number of premature deaths from liver disease witnessed a 3.7% increase, totaling 10,501 in 2021. Among these fatalities, 5,686 were attributed to alcohol-related liver disease in England, while non-alcoholic fatty liver disease accounted for 320 premature deaths. Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment market.

Advancements In Non-Alcoholic Steatohepatitis (NASH) Drug Development Transforming Treatment Landscape
The development of the non-alcoholic steatohepatitis (NASH) drug is a key trend gaining popularity in the non-alcoholic steatohepatitis treatment market. Many companies are investing in developing innovative drugs for the treatment of liver diseases with reduced side effects of the drugs. For instance, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology company, received a grant from U.S. Food and Drug Administration (FDA) for fast-track designation to facilitate the development of the non-alcoholic steatohepatitis (NASH) drug, namely ervogastat and clesacostat. Fast Track is a process designed to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis named as; ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

The non-alcoholic steatohepatitis treatment market covered in this report is segmented -

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=8595&type=discount

Major companies operating in the non-alcoholic steatohepatitis treatment market report are AstraZeneca Plc, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corp., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Gemphire Therapeutics Inc., Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Sinew Pharma Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG, Asahi Kasei Corporation

Contents of the report:
1. Executive Summary
2. Non-Alcoholic Steatohepatitis Treatment Market Report Structure
3. Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies
4. Non-Alcoholic Steatohepatitis Treatment Market - Macro Economic Scenario
5. Non-Alcoholic Steatohepatitis Treatment Market Size And Growth
…..
27. Non-Alcoholic Steatohepatitis Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.